Will cases of leprosy reaction increase with COVID-19 infection?
In the T1R, the type 1 helper (Th1) response predominates in lesions and the serum of patients with high levels of cytokines tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), interleukin-17 (IL-17), and C-X-C motif chemokine 10 (CXCL10) [9]. The anti-inflammatory and immunosuppressive e...
Gespeichert in:
| Veröffentlicht in: | PLoS neglected tropical diseases 2020-07, Vol.14 (7), p.e0008460, Article 0008460 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 7 |
| container_start_page | e0008460 |
| container_title | PLoS neglected tropical diseases |
| container_volume | 14 |
| creator | Antunes, Douglas Eulalio Bernardes Goulart, Isabela Maria Goulart, Luiz Ricardo |
| description | In the T1R, the type 1 helper (Th1) response predominates in lesions and the serum of patients with high levels of cytokines tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), interleukin-17 (IL-17), and C-X-C motif chemokine 10 (CXCL10) [9]. The anti-inflammatory and immunosuppressive effects of glucocorticoids are dose dependent. [...]at high doses, their effects are immunosuppressive, causing emerging infections, such as COVID-19, in these susceptible patients [17]. Even though some clinical trials are underway to investigate the use of thalidomide—alone or combined with systemic glucocorticoids, such as methylprednisolone—to treat moderate and severe COVID-19 pneumonia, there are no final conclusions ensuring that they are an effective treatment [20]. [...]we believe that, as the number of new cases of COVID-19 infection increases, the incidence of leprosy reactions may also increase considerably. [...]for leprosy patients on treatment or after discharge from MDT, we recommend what medical doctors and health teams advise with the goal to avoid exposure to SARS-CoV-2, such as the following: the use of masks in the community; stay home and self-isolate from others; wash hands regularly for 20 seconds, with soap and water or alcohol-based hand rub; avoid close contact (staying 2 meters away from other people); and cover your nose and mouth with a disposable tissue or flexed elbow when you cough or sneeze. |
| doi_str_mv | 10.1371/journal.pntd.0008460 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_2434499769</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A632968260</galeid><doaj_id>oai_doaj_org_article_aca0d42ca69843e48bf81daa49942d7f</doaj_id><sourcerecordid>A632968260</sourcerecordid><originalsourceid>FETCH-LOGICAL-c624t-5db5e1fefcf99a2c2e7117150ccc704fa657527d93241109b8ff3535b07535213</originalsourceid><addsrcrecordid>eNqNkm2L1DAQx4so3nn6DUQLgm-ka57TvFGP-rRwcG98eBnSdLKbpdusTetx3970trfsgoIEkmHym39mMpNlzzFaYCrx200Y-860i103NAuEUMkEepCdY0V5QSTlD4_ss-xJjBuEuOIlfpydUSJkWWJxnn346ds2tyZCzIPLW9j1Id7mPRg7-NDlvrPJjpDf-GGdV9c_lh8LrJLbwR3w_mn2yJk2wrP5vMi-f_70rfpaXF1_WVaXV4UVhA0Fb2oO2IGzTilDLAGJscQcWWslYs4ILjmRjaKEYYxUXTpHOeU1kmknmF5kL_e6uzZEPRcfNWGUMaWkUIlY7okmmI3e9X5r-lsdjNd3jtCvtOkHb1vQxhrUMGKNUCWjwMralbgxJikx0kiXtN7Nr431FhoL3dCb9kT09Kbza70Kv7WkQjLGksCrWaAPv0aIwz9SnqmVSVmlTw1JzG59tPpSUKJESQRK1OIvVFoNbL0NHTif_CcBr48C1mDaYR1DO04Ni6cg24M2dT324A4VYqSnKbvPWk9TpucpS2Evjn_nEHQ_Vgl4swduoA4uWg-dhQOWZDhnjCuaLDS1tvx_uvKDmeqowtgN9A8K8u1I</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2434499769</pqid></control><display><type>article</type><title>Will cases of leprosy reaction increase with COVID-19 infection?</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>Public Library of Science (PLoS)</source><source>Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><source>PubMed Central</source><creator>Antunes, Douglas Eulalio ; Bernardes Goulart, Isabela Maria ; Goulart, Luiz Ricardo</creator><contributor>Samy, Abdallah M.</contributor><creatorcontrib>Antunes, Douglas Eulalio ; Bernardes Goulart, Isabela Maria ; Goulart, Luiz Ricardo ; Samy, Abdallah M.</creatorcontrib><description>In the T1R, the type 1 helper (Th1) response predominates in lesions and the serum of patients with high levels of cytokines tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), interleukin-17 (IL-17), and C-X-C motif chemokine 10 (CXCL10) [9]. The anti-inflammatory and immunosuppressive effects of glucocorticoids are dose dependent. [...]at high doses, their effects are immunosuppressive, causing emerging infections, such as COVID-19, in these susceptible patients [17]. Even though some clinical trials are underway to investigate the use of thalidomide—alone or combined with systemic glucocorticoids, such as methylprednisolone—to treat moderate and severe COVID-19 pneumonia, there are no final conclusions ensuring that they are an effective treatment [20]. [...]we believe that, as the number of new cases of COVID-19 infection increases, the incidence of leprosy reactions may also increase considerably. [...]for leprosy patients on treatment or after discharge from MDT, we recommend what medical doctors and health teams advise with the goal to avoid exposure to SARS-CoV-2, such as the following: the use of masks in the community; stay home and self-isolate from others; wash hands regularly for 20 seconds, with soap and water or alcohol-based hand rub; avoid close contact (staying 2 meters away from other people); and cover your nose and mouth with a disposable tissue or flexed elbow when you cough or sneeze.</description><identifier>ISSN: 1935-2735</identifier><identifier>ISSN: 1935-2727</identifier><identifier>EISSN: 1935-2735</identifier><identifier>DOI: 10.1371/journal.pntd.0008460</identifier><identifier>PMID: 32678816</identifier><language>eng</language><publisher>SAN FRANCISCO: Public Library Science</publisher><subject>Alcohols ; Betacoronavirus ; Biology and Life Sciences ; Care and treatment ; Chemokines ; Clinical trials ; Coronavirus Infections - epidemiology ; Coronaviruses ; Cough ; COVID-19 ; CXCL10 protein ; Cytokines ; Development and progression ; Doctors ; Drug dosages ; Elbow ; Glucocorticoids ; Health services ; Humans ; Incidence ; Infections ; Infectious Diseases ; Inflammation ; Interferon ; Interleukin ; Interleukin 17 ; Interleukins ; Leprostatic Agents - adverse effects ; Leprostatic Agents - therapeutic use ; Leprosy ; Leprosy - drug therapy ; Leprosy - epidemiology ; Lesions ; Life Sciences & Biomedicine ; Lymphocytes T ; Masks ; Medical research ; Medicine and Health Sciences ; Methylprednisolone ; Necroses ; Necrosis ; Neoplasms ; Pandemics ; Parasitology ; Patients ; Physicians ; Pneumonia, Viral - epidemiology ; Preventive medicine ; Risk factors ; SARS-CoV-2 ; Science & Technology ; Serum ; Severe acute respiratory syndrome coronavirus 2 ; Thalidomide ; Tropical diseases ; Tropical Medicine ; Tumor necrosis factor-α ; Tumours ; Viewpoints ; γ-Interferon</subject><ispartof>PLoS neglected tropical diseases, 2020-07, Vol.14 (7), p.e0008460, Article 0008460</ispartof><rights>COPYRIGHT 2020 Public Library of Science</rights><rights>2020 Antunes et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 Antunes et al 2020 Antunes et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>18</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000554459300001</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c624t-5db5e1fefcf99a2c2e7117150ccc704fa657527d93241109b8ff3535b07535213</citedby><cites>FETCH-LOGICAL-c624t-5db5e1fefcf99a2c2e7117150ccc704fa657527d93241109b8ff3535b07535213</cites><orcidid>0000-0001-8091-7158 ; 0000-0003-2319-3223</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367444/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367444/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,865,886,2103,2115,2929,23871,27929,27930,28253,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32678816$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Samy, Abdallah M.</contributor><creatorcontrib>Antunes, Douglas Eulalio</creatorcontrib><creatorcontrib>Bernardes Goulart, Isabela Maria</creatorcontrib><creatorcontrib>Goulart, Luiz Ricardo</creatorcontrib><title>Will cases of leprosy reaction increase with COVID-19 infection?</title><title>PLoS neglected tropical diseases</title><addtitle>PLOS NEGLECT TROP D</addtitle><addtitle>PLoS Negl Trop Dis</addtitle><description>In the T1R, the type 1 helper (Th1) response predominates in lesions and the serum of patients with high levels of cytokines tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), interleukin-17 (IL-17), and C-X-C motif chemokine 10 (CXCL10) [9]. The anti-inflammatory and immunosuppressive effects of glucocorticoids are dose dependent. [...]at high doses, their effects are immunosuppressive, causing emerging infections, such as COVID-19, in these susceptible patients [17]. Even though some clinical trials are underway to investigate the use of thalidomide—alone or combined with systemic glucocorticoids, such as methylprednisolone—to treat moderate and severe COVID-19 pneumonia, there are no final conclusions ensuring that they are an effective treatment [20]. [...]we believe that, as the number of new cases of COVID-19 infection increases, the incidence of leprosy reactions may also increase considerably. [...]for leprosy patients on treatment or after discharge from MDT, we recommend what medical doctors and health teams advise with the goal to avoid exposure to SARS-CoV-2, such as the following: the use of masks in the community; stay home and self-isolate from others; wash hands regularly for 20 seconds, with soap and water or alcohol-based hand rub; avoid close contact (staying 2 meters away from other people); and cover your nose and mouth with a disposable tissue or flexed elbow when you cough or sneeze.</description><subject>Alcohols</subject><subject>Betacoronavirus</subject><subject>Biology and Life Sciences</subject><subject>Care and treatment</subject><subject>Chemokines</subject><subject>Clinical trials</subject><subject>Coronavirus Infections - epidemiology</subject><subject>Coronaviruses</subject><subject>Cough</subject><subject>COVID-19</subject><subject>CXCL10 protein</subject><subject>Cytokines</subject><subject>Development and progression</subject><subject>Doctors</subject><subject>Drug dosages</subject><subject>Elbow</subject><subject>Glucocorticoids</subject><subject>Health services</subject><subject>Humans</subject><subject>Incidence</subject><subject>Infections</subject><subject>Infectious Diseases</subject><subject>Inflammation</subject><subject>Interferon</subject><subject>Interleukin</subject><subject>Interleukin 17</subject><subject>Interleukins</subject><subject>Leprostatic Agents - adverse effects</subject><subject>Leprostatic Agents - therapeutic use</subject><subject>Leprosy</subject><subject>Leprosy - drug therapy</subject><subject>Leprosy - epidemiology</subject><subject>Lesions</subject><subject>Life Sciences & Biomedicine</subject><subject>Lymphocytes T</subject><subject>Masks</subject><subject>Medical research</subject><subject>Medicine and Health Sciences</subject><subject>Methylprednisolone</subject><subject>Necroses</subject><subject>Necrosis</subject><subject>Neoplasms</subject><subject>Pandemics</subject><subject>Parasitology</subject><subject>Patients</subject><subject>Physicians</subject><subject>Pneumonia, Viral - epidemiology</subject><subject>Preventive medicine</subject><subject>Risk factors</subject><subject>SARS-CoV-2</subject><subject>Science & Technology</subject><subject>Serum</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Thalidomide</subject><subject>Tropical diseases</subject><subject>Tropical Medicine</subject><subject>Tumor necrosis factor-α</subject><subject>Tumours</subject><subject>Viewpoints</subject><subject>γ-Interferon</subject><issn>1935-2735</issn><issn>1935-2727</issn><issn>1935-2735</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>AOWDO</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>DOA</sourceid><recordid>eNqNkm2L1DAQx4so3nn6DUQLgm-ka57TvFGP-rRwcG98eBnSdLKbpdusTetx3970trfsgoIEkmHym39mMpNlzzFaYCrx200Y-860i103NAuEUMkEepCdY0V5QSTlD4_ss-xJjBuEuOIlfpydUSJkWWJxnn346ds2tyZCzIPLW9j1Id7mPRg7-NDlvrPJjpDf-GGdV9c_lh8LrJLbwR3w_mn2yJk2wrP5vMi-f_70rfpaXF1_WVaXV4UVhA0Fb2oO2IGzTilDLAGJscQcWWslYs4ILjmRjaKEYYxUXTpHOeU1kmknmF5kL_e6uzZEPRcfNWGUMaWkUIlY7okmmI3e9X5r-lsdjNd3jtCvtOkHb1vQxhrUMGKNUCWjwMralbgxJikx0kiXtN7Nr431FhoL3dCb9kT09Kbza70Kv7WkQjLGksCrWaAPv0aIwz9SnqmVSVmlTw1JzG59tPpSUKJESQRK1OIvVFoNbL0NHTif_CcBr48C1mDaYR1DO04Ni6cg24M2dT324A4VYqSnKbvPWk9TpucpS2Evjn_nEHQ_Vgl4swduoA4uWg-dhQOWZDhnjCuaLDS1tvx_uvKDmeqowtgN9A8K8u1I</recordid><startdate>20200701</startdate><enddate>20200701</enddate><creator>Antunes, Douglas Eulalio</creator><creator>Bernardes Goulart, Isabela Maria</creator><creator>Goulart, Luiz Ricardo</creator><general>Public Library Science</general><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>AOWDO</scope><scope>BLEPL</scope><scope>DTL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7SS</scope><scope>7T2</scope><scope>7T7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8C1</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>F1W</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>H95</scope><scope>H97</scope><scope>K9.</scope><scope>L.G</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-8091-7158</orcidid><orcidid>https://orcid.org/0000-0003-2319-3223</orcidid></search><sort><creationdate>20200701</creationdate><title>Will cases of leprosy reaction increase with COVID-19 infection?</title><author>Antunes, Douglas Eulalio ; Bernardes Goulart, Isabela Maria ; Goulart, Luiz Ricardo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c624t-5db5e1fefcf99a2c2e7117150ccc704fa657527d93241109b8ff3535b07535213</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Alcohols</topic><topic>Betacoronavirus</topic><topic>Biology and Life Sciences</topic><topic>Care and treatment</topic><topic>Chemokines</topic><topic>Clinical trials</topic><topic>Coronavirus Infections - epidemiology</topic><topic>Coronaviruses</topic><topic>Cough</topic><topic>COVID-19</topic><topic>CXCL10 protein</topic><topic>Cytokines</topic><topic>Development and progression</topic><topic>Doctors</topic><topic>Drug dosages</topic><topic>Elbow</topic><topic>Glucocorticoids</topic><topic>Health services</topic><topic>Humans</topic><topic>Incidence</topic><topic>Infections</topic><topic>Infectious Diseases</topic><topic>Inflammation</topic><topic>Interferon</topic><topic>Interleukin</topic><topic>Interleukin 17</topic><topic>Interleukins</topic><topic>Leprostatic Agents - adverse effects</topic><topic>Leprostatic Agents - therapeutic use</topic><topic>Leprosy</topic><topic>Leprosy - drug therapy</topic><topic>Leprosy - epidemiology</topic><topic>Lesions</topic><topic>Life Sciences & Biomedicine</topic><topic>Lymphocytes T</topic><topic>Masks</topic><topic>Medical research</topic><topic>Medicine and Health Sciences</topic><topic>Methylprednisolone</topic><topic>Necroses</topic><topic>Necrosis</topic><topic>Neoplasms</topic><topic>Pandemics</topic><topic>Parasitology</topic><topic>Patients</topic><topic>Physicians</topic><topic>Pneumonia, Viral - epidemiology</topic><topic>Preventive medicine</topic><topic>Risk factors</topic><topic>SARS-CoV-2</topic><topic>Science & Technology</topic><topic>Serum</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Thalidomide</topic><topic>Tropical diseases</topic><topic>Tropical Medicine</topic><topic>Tumor necrosis factor-α</topic><topic>Tumours</topic><topic>Viewpoints</topic><topic>γ-Interferon</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Antunes, Douglas Eulalio</creatorcontrib><creatorcontrib>Bernardes Goulart, Isabela Maria</creatorcontrib><creatorcontrib>Goulart, Luiz Ricardo</creatorcontrib><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ASFA: Aquatic Sciences and Fisheries Abstracts</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) 3: Aquatic Pollution & Environmental Quality</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) Professional</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PLoS neglected tropical diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Antunes, Douglas Eulalio</au><au>Bernardes Goulart, Isabela Maria</au><au>Goulart, Luiz Ricardo</au><au>Samy, Abdallah M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Will cases of leprosy reaction increase with COVID-19 infection?</atitle><jtitle>PLoS neglected tropical diseases</jtitle><stitle>PLOS NEGLECT TROP D</stitle><addtitle>PLoS Negl Trop Dis</addtitle><date>2020-07-01</date><risdate>2020</risdate><volume>14</volume><issue>7</issue><spage>e0008460</spage><pages>e0008460-</pages><artnum>0008460</artnum><issn>1935-2735</issn><issn>1935-2727</issn><eissn>1935-2735</eissn><abstract>In the T1R, the type 1 helper (Th1) response predominates in lesions and the serum of patients with high levels of cytokines tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), interleukin-17 (IL-17), and C-X-C motif chemokine 10 (CXCL10) [9]. The anti-inflammatory and immunosuppressive effects of glucocorticoids are dose dependent. [...]at high doses, their effects are immunosuppressive, causing emerging infections, such as COVID-19, in these susceptible patients [17]. Even though some clinical trials are underway to investigate the use of thalidomide—alone or combined with systemic glucocorticoids, such as methylprednisolone—to treat moderate and severe COVID-19 pneumonia, there are no final conclusions ensuring that they are an effective treatment [20]. [...]we believe that, as the number of new cases of COVID-19 infection increases, the incidence of leprosy reactions may also increase considerably. [...]for leprosy patients on treatment or after discharge from MDT, we recommend what medical doctors and health teams advise with the goal to avoid exposure to SARS-CoV-2, such as the following: the use of masks in the community; stay home and self-isolate from others; wash hands regularly for 20 seconds, with soap and water or alcohol-based hand rub; avoid close contact (staying 2 meters away from other people); and cover your nose and mouth with a disposable tissue or flexed elbow when you cough or sneeze.</abstract><cop>SAN FRANCISCO</cop><pub>Public Library Science</pub><pmid>32678816</pmid><doi>10.1371/journal.pntd.0008460</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0001-8091-7158</orcidid><orcidid>https://orcid.org/0000-0003-2319-3223</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1935-2735 |
| ispartof | PLoS neglected tropical diseases, 2020-07, Vol.14 (7), p.e0008460, Article 0008460 |
| issn | 1935-2735 1935-2727 1935-2735 |
| language | eng |
| recordid | cdi_proquest_journals_2434499769 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; Public Library of Science (PLoS); Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; PubMed Central |
| subjects | Alcohols Betacoronavirus Biology and Life Sciences Care and treatment Chemokines Clinical trials Coronavirus Infections - epidemiology Coronaviruses Cough COVID-19 CXCL10 protein Cytokines Development and progression Doctors Drug dosages Elbow Glucocorticoids Health services Humans Incidence Infections Infectious Diseases Inflammation Interferon Interleukin Interleukin 17 Interleukins Leprostatic Agents - adverse effects Leprostatic Agents - therapeutic use Leprosy Leprosy - drug therapy Leprosy - epidemiology Lesions Life Sciences & Biomedicine Lymphocytes T Masks Medical research Medicine and Health Sciences Methylprednisolone Necroses Necrosis Neoplasms Pandemics Parasitology Patients Physicians Pneumonia, Viral - epidemiology Preventive medicine Risk factors SARS-CoV-2 Science & Technology Serum Severe acute respiratory syndrome coronavirus 2 Thalidomide Tropical diseases Tropical Medicine Tumor necrosis factor-α Tumours Viewpoints γ-Interferon |
| title | Will cases of leprosy reaction increase with COVID-19 infection? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T17%3A52%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Will%20cases%20of%20leprosy%20reaction%20increase%20with%20COVID-19%20infection?&rft.jtitle=PLoS%20neglected%20tropical%20diseases&rft.au=Antunes,%20Douglas%20Eulalio&rft.date=2020-07-01&rft.volume=14&rft.issue=7&rft.spage=e0008460&rft.pages=e0008460-&rft.artnum=0008460&rft.issn=1935-2735&rft.eissn=1935-2735&rft_id=info:doi/10.1371/journal.pntd.0008460&rft_dat=%3Cgale_proqu%3EA632968260%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2434499769&rft_id=info:pmid/32678816&rft_galeid=A632968260&rft_doaj_id=oai_doaj_org_article_aca0d42ca69843e48bf81daa49942d7f&rfr_iscdi=true |